Chronic and acute decompensated heart failure: topical issues

Highlights. The article is a review of current literary data on the problem of acute decompensated heart failure. The review highlights the basic principles of the diagnosis and treatment, as well as the problems of their implementation into clinical practice.

Abstract Acute decompensated heart failure (ADHF) is a life-threatening condition that requires an emergency hospitalization for intensive treatment. Moreover, it is the event that worsens the patient's further prognosis. Frequent rehospitalizations for decompensation of heart failure reduce life expectancy and quality, and are also a significant economic problem in practical health care. The increasing number of patients with heart failure leads to the growing number of patients seeking medical help for acute decompensated heart failure. More than half of the patients are re-hospitalized within a year for the same reason. The predicted increase in the prevalence of CHF worldwide makes the management of such patients a global medical and social problem. Patients delay, low compliance and insufficient ambulatory monitoring are the factors that need to be influenced in order to improve the prognosis. The article is a review of literary data on the epidemiology of ADHF, diagnosis, treatment and outpatient observation of patients with acute decompensated heart failure. The problems of compliance, the prospects for modern methods of remote monitoring and the possibilities of new drugs are discussed in the article.

1. Mareev V.YU., Fomin I.V., Ageev F.T., Begrambekova YU.L., Vasyuk YU.A., Garganeeva A.A. Russian heart failure society, russian society of cardiology. russian scientific medical society of internal medicine guidelines for heart failure: chronic (chf) and acute decompensated (adhf). diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russian) doi:10.18087/cardio.2475

2. Lippi G., Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J 2020;5:15. doi:10.21037/amj.2020.03.03

3. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016;21(8):7-13. (In Russian) doi:10.15829/1560-4071-2016-8-7-13

4. Fomin I.V. Epidemiologiya khronicheskoy serdechnoy nedostatochnosti v Rossiyskoy Federatsii. Khronicheskaya serdechnaya nedostatochnost'. Moscow: GEOTAR-Media; 2010. (In Russian)

5. Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Badin Yu.V., Galyavich A.S., Danielyan M.O., Kamalov G.M., Kolbin A.A., Kechedzhieva S.G., Makarova V.G., Makarova N.V., Malenkova V.Yu., Sayfutdinov R.I., Tarlovskaya E.I., Khokhlov R.A., Shcherbinina E. .V., Yakushin S.S.. Prevalence of chronic heart failure in European part of Russian Federation: Data from epoch-chf. (Part II). Russian Heart Failure Journal. 2006;7(3(37):112-115. (In Russian)

6. Zhirov I.V., Romanova N.V., Tereshchenko S.N., Osmolovskaya Yu.F. Epidemiology and management of heart failure patients with atrial fibrillation. Kardiologiia. 2015;55(3):91-96. (In Russian) doi:10.18565/cardio.2015.3.91-96

7. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russian) doi:10.15829/1560-4071-2020-4083

8. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J., Coats A., Falk V., Gonzalez-Juanatey J.R., Harjola V., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G., Ruilope L.M., Ruschitzka F., Rutten F.H., Meer P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128

9. Arutyunov A.G., Rylova A.K., Arutyunov G.P. Registr gospitalizirovannykh patsientov s dekompensatsiey krovoobrashcheniya (registr Pavlovskoy bol'nitsy). Soobshchenie 2. Klinicheskoe znachenie i prognosticheskaya rol' nekotorykh parametrov, opredelyaemykh pri fizikal'nom i instrumental'nom obsledovanii patsientov s dekompensatsiey krovoobrashcheniya. Russian heart failure journal. 2014;15(2(83):67-75. (In Russian) doi:10.18087/rhfj.2014.2.1934

10. Chioncel O., Mebazaa A., Maggioni A.P., Harjola V.P., Rosano G., Laroche C., Piepoli M.F., Crespo-Leiro M.G., Lainscak M., Ponikowski P., Filippatos G., Ruschitzka F., Seferovic P., Coats A.J.S., Lund L.H.; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338-1352. doi:10.1002/ejhf.1492

11. Koziolova N.A., Veklich A.S., Karavaev P.G. Risk factors for acute decompensated heart failure in type 2 diabetes patients. Russian journal of cardiology. 2020;25(4):19-26. (In Russian) doi:10.15829/1560-4071-2020-4-3717

12. Verbrugge F.H., Guazzi M., Testani J.M., Borlaug B.A. Altered hemodynamics and end-organ damage in heart failure: impact on the Lung and kidney. Circulation. 2020;142(10):998- 1012. doi:10.1161/CIRCULATIONAHA.119.045409

13. Gilyarevsky S.R. Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology. 2021;26(10):4699. (In Russian). doi:10.15829/1560-4071-2021-4699

14. Kitakata H., Kohno T., Kohsaka S., Shiraishi Y., Parizo J.T., Niimi N., Goda A., Nishihata Y., Heidenreich P.A., Yoshikawa T. Prognostic implications of early and midrange readmissions after acute heart failure hospitalizations: a report from a Japanese multicenter registry. J Am Heart Assoc. 2020;9:e014949. doi:10.1161/JAHA.119.014949

15. Vinogradova N.G., Polyakov D.S., Fomin I.V. The risks of re-hospitalization of patients with heart failure with prolonged follow-up in a specialized center for the treatment of heart failure and in real clinical practice. Kardiologiia. 2020;60(3):59-69. (In Russian). doi:10.18087/cardio.2020.3.n1002

16. Kanorskii S.G., Vasuk Y.A., Gridasova R.A., Kastanayan A.A., Pagaev F.P., Sadovoy V.I., Sidorov R.V., Terent’ev V.P., Tuaeva I.B., Frolov D.V., Khaisheva L.A., Khripun A.V., Chesnikova A.I. Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don). Kardiologiia. 2019;59(9):97-100. (In Russian). doi:10.18087/cardio.2019.9.n671

17. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., Cleland J.G.F., Coats A.J.S., Crespo-Leiro M.G., Farmakis D., Gilard M., Heymans S., Hoes A.W., Jaarsma T., Jankowska E.A., Lainscak M., Lam C.S.P., Lyon A.R., McMurray J.J.V., Mebazaa A., Mindham R., Muneretto C., Francesco Piepoli M., Price S., Rosano G.M.C., Ruschitzka F., Kathrine Skibelund A.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

18. Gohar A., Rutten F.H., den Ruijter H., Kelder J.C., von Haehling S., Anker S.D., Möckel M., Hoes A.W. Mid-regional pro-atrial natriuretic peptide for the early detection of nonacute heart failure. Eur J Heart Fail. 2019;21(10):1219-1227. doi:10.1002/ejhf.1495

19. Mueller C., McDonald K., de Boer R.A., Maisel A., Cleland J.G.F., Kozhuharov N., Coats A.J.S., Metra M., Mebazaa A., Ruschitzka F., Lainscak M., Filippatos G., Seferovic P.M., Meijers W.C., Bayes-Genis A., Mueller T., Richards M., Januzzi J.L. Jr.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. doi: 10.1002/ejhf.1494

20. Glizer S.L., Shtegman O.A., Petrova M.M. Biomarkers and the prediction of adverse outcomes in patients with acute decompensated heart failure and kidney injury. Complex Issues of Cardiovascular Diseases. 2021;10(3):65-71. (In Russian) doi:10.17802/2306-1278-2021-10-3-65-71

21. Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacol Ther. 2021;227:107863. doi: 10.1016/j.pharmthera.2021.107863.

22. Kopeva K.V., Grakova E.V., Teplyakov A.T. New biomarkers of heart failure: diagnostic and prognostic value of nt-probnp and interleukin receptor family member st2. Kompleksnye problemy serdechno-sosudistykh zabolevaniy. 2018;7(1):94-101. (In Russian). doi:10.17802/2306-1278-2018-7-1-94-101

23. Fitzsimons S., Doughty R.N. Role of transthoracic echocardiogram in acute heart failure. Rev Cardiovasc Med. 2021;22(3):741-754. doi:10.31083/j.rcm2203081

24. Zhirov I.V., Tereshchenko S.N., Pavlenko T.A. Usage of lung ultrasound for diagnostics of heart failure Decompensation and control of diuretic therapy. Neotlozhnaja kardiologija. 2019;2:24-34. (In Russian). doi:10.25679/EMERGCARDIOLOGY.2019.23.97.003

25. Reddy Y.N.V., Borlaug B.A., O'Connor C.M., Gersh B.J. Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. Eur Heart J. 2020;41(18):1764-1774. doi:10.1093/eurheartj/ehz364.

26. Packer M., Claggett B., Lefkowitz M.P., McMurray J.J.V., Rouleau J.L., Solomon S.D., Zile M.R. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547-554. doi:10.1016/S2213-8587(18)30100-1

27. Teerlink J.R., Diaz R., Felker G.M., McMurray J.J.V., Metra M., Solomon S.D., Adams K.F., Anand I., AriasMendoza A., Biering-Sørensen T., Böhm M., Bonderman D., Cleland J.G.F.,Corbalan R., Crespo-Leiro M.G., Dahlström U., Echeverria L.E., Fang J.C., Filippatos G., Fonseca C., Goncalvesova E., Goudev A.R., Howlett J.G., Lanfear D.E., Li J., Lund M., Macdonald P., Mareev V., Momomura S.I., O'Meara E., Parkhomenko A., Ponikowski P., Ramires F.J.A., Serpytis P., Sliwa K., Spinar J., Suter T.M., Tomcsanyi J., Vandekerckhove H., Vinereanu D., Voors A.A., Yilmaz M.B., Zannad F., Sharpsten L., Legg J.C., Varin C., Honarpour N., Abbasi S.A., Malik F.I., Kurtz C.E.; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021;384(2):105-116. doi:10.1056/NEJMoa2025797

28. Packer M., Anker S.D., Butler J., Filippatos G., Ferreira J.P., Pocock S.J., Sattar N., Brueckmann M., Jamal W., Cotton D., Iwata T., Zannad F.; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPERORReduced Trial. J Am Coll Cardiol. 2021;77(11):1381-1392. doi: 10.1016/j.jacc.2021.01.033.

29. Bavry A. A. Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE. ACC. 2021. Available at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/11/12/00/29/EMPULSE. (accessed: 30 November, 2021).

30. Gioeva Z.M., Bogdanov A.R., Zaletova T.S., Bogdanova A.A. Obesity as a risk factor for chronic heart failure: a review of the literature. Doctor.ru. 2017;10(139):21-25. (In Russian)

31. Mughal M.S., Ghani A.R., Kumar S., Hanif W., Ahsan I., Akbar H., Aslam S., Khakwani Z., Mikhalkova D., Levitt H. Heart Failure Patients and Implications of Obesity: A SingleCenter Retrospective Study. Cureus. 2021;13(9):e18140. doi:10.7759/cureus.18140

32. Vest A.R., Chan M., Deswal A., Givertz M.M., Lekavich C., Lennie T., Litwin S.E., Parsly L., Rodgers J.E., Rich M.W., Schulze P.C., Slader A., Desai A. Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019;25(5):380-400. doi: 10.1016/j.cardfail.2019.03.007

33. Carbone S., Lavie C.J., Elagizi A., Arena R., Ventura H.O. The Impact of Obesity in Heart Failure. Heart Fail Clin. 2020;16(1):71-80. doi:10.1016/j.hfc.2019.08.008

34. Pelliccia A., Sharma S., Gati S., Bäck M., Börjesson M., Caselli S., Collet J., Corrado D., Drezner J., Halle M., Hansen D., Heidbuchel H., Myers J., Niebauer J., Papadakis M., Piepoli M., Prescott E., RoosHesselink J., Stuart A., Taylor R., Thompson P., Tiberi M., Vanhees L., Wilhelm M. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Russian Journal of Cardiology. 2021;26(5):4488. (In Russian) doi: 10.15829/1560-4071-2021-4488

35. Khan M.S., Jones D.W., Butler J. Salt, No Salt, or Less Salt for Patients With Heart Failure? Am J Med. 2020;133(1):32- 38. doi:10.1016/j.amjmed.2019.07.034

36. Neal B., Wu Y., Feng X., Zhang R., Zhang Y., Shi J., Zhang J., Tian M., Huang L., Li Z., Yu Y., Zhao Y., Zhou B., Sun J., Liu Y., Yin X., Hao Z., Yu J., Li K.C., Zhang X., Duan P., Wang F., Ma B., Shi W., Di Tanna G.L., Stepien S., Shan S., Pearson S.A., Li N., Yan L.L., Labarthe D., Elliott P. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385(12):1067-1077. doi:10.1056/NEJMoa2105675

37. Drapkina O.M., Karamnova N.S., Kontsevaya A.V., Gorny B.E., Dadaeva V.A., Drozdova L. YU., Yeganyan R.A., Eliashevich S.O., Izmailova O.V., Lavrenova E.A., Lischenko O.V., Skripnikova I.A., Shvabskaya O.B., Shishkova V.N. Alimentary-dependent risk factors for chronic non-communicable diseases and eating habits: *dietary correction within the framework of preventive counseling. methodological guidance. Cardiovascular therapy and prevention2021;20(5):2952. (In Russian). doi:10.15829/1728-8800-2021-2952 (In Russian)

38. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H., Halvorsen S., Hobbs F.D.R., Hollander M., Jankowska E.A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K.P., van Dis I., van Gelder I.C., Wanner C., Williams B.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484

39. Ramage-Morin P.L., Garriguet D. Nutritional risk among older Canadians. Health Rep. 2013;24(3):3-13.

40. Carbone .S, Billingsley H.E., Rodriguez-Miguelez P., Kirkman D.L., Garten R., Franco R.L., Lee D.C., Lavie C.J. Lean Mass Abnormalities in Heart Failure: The Role of Sarcopenia, Sarcopenic Obesity, and Cachexia. Curr Probl Cardiol. 2020;45(11):100417. doi: 10.1016/j.cpcardiol.2019.03.006

41. Billingsley H.E., Hummel S.L., Carbone S. The role of diet and nutrition in heart failure: A state-of-the-art narrative review. Prog Cardiovasc Dis. 2020;63(5):538-551. doi: 10.1016/j.pcad.2020.08.004

42. Vardeny O., Claggett B., Udell J.A., Packer M., Zile M., Rouleau J., Swedberg K., Desai A.S,. Lefkowitz M., Shi V., McMurray J.J.V., Solomon S.D.; PARADIGM-HF Investigators. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016;4(2):152-158. doi:10.1016/j.jchf.2015.10.012

43. Wu W.C., Jiang L., Friedmann P.D., Trivedi A. Association between process quality measures for heart failure and mortality among US veterans. Am Heart J. 2014;168(5):713- 270. doi:10.1016/j.ahj.2014.06.024

44. Rosano G., Jankowska E.A., Ray R., Metra M., Abdelhamid M., Adamopoulos S., Anker S.D., Bayes-Genis A., Belenkov Y., Gal T.B., Böhm M., Chioncel O., Cohen-Solal A., Farmakis D., Filippatos G., González A., Gustafsson F., Hill L., Jaarsma T., Jouhra F., Lainscak M., Lambrinou E., Lopatin Y., Lund L.H., Milicic D., Moura B., Mullens W., Piepoli M.F., Ponikowski P., Rakisheva A., Ristic A., Savarese G., Seferovic P., Senni M., Thum T., Tocchetti C.G., Van Linthout S., Volterrani M., Coats A.J.S. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(11): 1806-1818 doi:10.1002/ejhf.2356

45. Agrinier N., Schockmel M., Thilly N., Laborde-Castérot H., Jourdain P., Alla F., Leclercq C., Dany F., Druelle J., Drouet E., Mulak G., Juillière Y.; ODIN cohort participants. Effectiveness of a patient education programme in heart failure with preserved ejection fraction: Results from the ODIN cohort study using propensity score matching. Arch Cardiovasc Dis. 2018;111(1):5-16. https://doi.org/10.1016/j.acvd.2017.03.010

46. Demkina A.E., Vladzimirskiy A.V., Morozov S.P., Artemova O.R., Ryabinina M.N., Vorob'ev A.S. E-health in patients with chronic heart failure: realities and prospects. Creative cardiology 2020;14(2): 150-157. doi:10.24022/1997-3187-2020-14-2-150-157 (In Russian)

47. Demkina A.E., Ryabinina M. N., Aksenova G. A. Benimetskaya K.S., Vasil'eva I.A., Isaeva A.V., Lobzhanidze F.A., Novikova D.S., Pivenshteyn A.N., Savonina O.A. Sotsial'nye seti i meditsinskie obrazovatel'nye programmy: vozmozhnosti i perspektivy. Russian cardiology bulletin. 2020;15(S):89.(In Russian)

48. Kalinina A.M., Kulikova M.S., Gomova T.A., Gorny B.E., Dubovoy I.I., Drapkina O.M. On the topic of demand and usage of the telemedicine model "doctor-patient" for the prevention and control of chronic diseases: the view of a primary health care doctor. The Russian journal of preventive medicine. 2021;24(6):28-36. doi:10.17116/profmed20212406128 (In Russian)

49. Kochergin N.A., Kochergina A.M., Kilina I.R., Kleshhenogov A.S., Leonova V.O. Possibility of mobile app usageas a tool to improve compliance for patients with cardiovascular disease, Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases. Medical doctor and it. 2017;2:73-80. (In Russian)